Low-Dose Fenfluramine Granted Orphan Status for LGS

Tuesday, June 27, 2017 | Epilepsy & Seizure Disorders , Phase 3/4 Trials


The FDA has granted orphan drug designation to ZX008 (Zogenix), an investigational treatment for Lennox Gastaut Syndrome (LGS). Zogenix will initiate a Phase 3 clinical trial in LGS in second half of this year. ZX008 is a low-dose fenfluramine liquid solution that is also under investigation for Dravet syndrome, for which it has also been granted orphan drug designation.

Next Story

Comments

You must be logged in to leave a comment.